188 related articles for article (PubMed ID: 24764685)
1. Death decoy receptor overexpression and increased malignancy risk in colorectal cancer.
Zong L; Chen P; Wang DX
World J Gastroenterol; 2014 Apr; 20(15):4440-5. PubMed ID: 24764685
[TBL] [Abstract][Full Text] [Related]
2. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
3. [Relationship between expression of decoy receptor 3 and apoptosis in hepatocellular carcinoma].
Chen G; Luo DZ; Wang Y; Liao ZL; Zhang MY
Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):113-7. PubMed ID: 17493386
[TBL] [Abstract][Full Text] [Related]
4. Over-expression of decoy receptor 3 in gastric precancerous lesions and carcinoma.
Chen G; Luo D
Ups J Med Sci; 2008; 113(3):297-304. PubMed ID: 18991242
[TBL] [Abstract][Full Text] [Related]
5. Decoy receptor 3 is a prognostic factor in renal cell cancer.
Macher-Goeppinger S; Aulmann S; Wagener N; Funke B; Tagscherer KE; Haferkamp A; Hohenfellner M; Kim S; Autschbach F; Schirmacher P; Roth W
Neoplasia; 2008 Oct; 10(10):1049-56. PubMed ID: 18813347
[TBL] [Abstract][Full Text] [Related]
6. DCR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer.
Mild G; Bachmann F; Boulay JL; Glatz K; Laffer U; Lowy A; Metzger U; Reuter J; Terracciano L; Herrmann R; Rochlitz C
Int J Cancer; 2002 Nov; 102(3):254-7. PubMed ID: 12397645
[TBL] [Abstract][Full Text] [Related]
7. DcR3 and survivin are highly expressed in colorectal carcinoma and closely correlated to its clinicopathologic parameters.
Liang QL; Wang BR; Li GH
J Zhejiang Univ Sci B; 2009 Sep; 10(9):675-82. PubMed ID: 19735100
[TBL] [Abstract][Full Text] [Related]
8. DcR3 induces epithelial-mesenchymal transition through activation of the TGF-β3/SMAD signaling pathway in CRC.
Liu YP; Zhu HF; Liu DL; Hu ZY; Li SN; Kan HP; Wang XY; Li ZG
Oncotarget; 2016 Nov; 7(47):77306-77318. PubMed ID: 27764793
[TBL] [Abstract][Full Text] [Related]
9. The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas.
Takahama Y; Yamada Y; Emoto K; Fujimoto H; Takayama T; Ueno M; Uchida H; Hirao S; Mizuno T; Nakajima Y
Gastric Cancer; 2002; 5(2):61-8. PubMed ID: 12111580
[TBL] [Abstract][Full Text] [Related]
10. Decoy Receptor 3 Expression Is Associated With Wild-Type EGFR Status, Poor Differentiation of Tumor, and Unfavorable Patient Outcome.
Chang WC; Yeh YC; Ho HL; Hsieh SL; Chou TY
Am J Clin Pathol; 2019 Jul; 152(2):207-216. PubMed ID: 31077284
[TBL] [Abstract][Full Text] [Related]
11. Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer.
Cho JH; Lim JY; Cho JY
World J Gastroenterol; 2017 Nov; 23(41):7407-7414. PubMed ID: 29151694
[TBL] [Abstract][Full Text] [Related]
12. Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer.
Lu Y; Jingyan G; Baorong S; Peng J; Xu Y; Cai S
Cancer Biomark; 2012; 11(5):219-26. PubMed ID: 23220854
[TBL] [Abstract][Full Text] [Related]
13. Decoy receptor 3 (DcR3) overexpression predicts the prognosis and pN2 in pancreatic head carcinoma.
Zhou J; Song S; Li D; He S; Zhang B; Wang Z; Zhu X
World J Surg Oncol; 2014 Mar; 12():52. PubMed ID: 24597666
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of DcR3 and its significance on tumor cell differentiation and proliferation in glioma.
Huang S; Chen G; Dang Y; Chen LH
ScientificWorldJournal; 2014; 2014():605236. PubMed ID: 24741354
[TBL] [Abstract][Full Text] [Related]
15. Prognosis of HER2 over-expressing gastric cancer patients with liver metastasis.
Dang HZ; Yu Y; Jiao SC
World J Gastroenterol; 2012 May; 18(19):2402-7. PubMed ID: 22654433
[TBL] [Abstract][Full Text] [Related]
16. Overexpression and clinicopathological contribution of DcR3 in bladder urothelial carcinoma tissues.
Jiang YQ; Zhong TF; Dang YW; Zou LS; Yang L; Yang X; Chen G
Asian Pac J Cancer Prev; 2014; 15(21):9137-42. PubMed ID: 25422191
[TBL] [Abstract][Full Text] [Related]
17. Decoy Receptor 3 (DcR3) as a Biomarker of Tumor Deterioration in Female Reproductive Cancers: A Meta-Analysis.
Jiang M; Lin X; He R; Lin X; Liang L; Tang R; Xiong D; Wei K; Dang Y; Feng Z; Chen G
Med Sci Monit; 2016 Jun; 22():1850-7. PubMed ID: 27246752
[TBL] [Abstract][Full Text] [Related]
18. The soluble Decoy Receptor 3 is regulated by a PI3K-dependent mechanism and promotes migration and invasion in renal cell carcinoma.
Weissinger D; Tagscherer KE; Macher-Göppinger S; Haferkamp A; Wagener N; Roth W
Mol Cancer; 2013 Oct; 12(1):120. PubMed ID: 24107265
[TBL] [Abstract][Full Text] [Related]
19. Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin's lymphoma.
Bedewy AM; Elgammal MM; Bedewy MM; El-Maghraby SM
Ann Hematol; 2013 Oct; 92(10):1359-67. PubMed ID: 23652586
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of expression and amplification of the DcR3 gene in pancreatic carcinomas.
Zhou J; Song SD; Li DC; Zhou J; Zhu DM; Zheng SY
Asian Pac J Cancer Prev; 2012; 13(2):719-24. PubMed ID: 22524850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
